HC Wainwright Has Negative Outlook for MBRX FY2025 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright reduced their FY2025 earnings per share estimates for Moleculin Biotech in a research note issued on Thursday, December 11th. HC Wainwright analyst S. Nik now forecasts that the company will post earnings of ($31.44) per share for the year, down from their prior forecast of ($21.25). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2025 earnings at ($12.69) EPS and FY2026 earnings at ($9.99) EPS.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07.

MBRX has been the topic of several other reports. Wall Street Zen cut shares of Moleculin Biotech to a “strong sell” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Wednesday, October 8th. Finally, Roth Capital reissued a “buy” rating on shares of Moleculin Biotech in a research note on Monday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $61.00.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX opened at $4.69 on Monday. The firm has a 50 day simple moving average of $10.08 and a 200 day simple moving average of $12.26. Moleculin Biotech has a 52 week low of $4.36 and a 52 week high of $91.25. The company has a market cap of $9.57 million, a PE ratio of -0.14 and a beta of 1.58.

Institutional Trading of Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC grew its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,250,000 shares of the company’s stock after purchasing an additional 932,414 shares during the period. Armistice Capital LLC owned about 8.93% of Moleculin Biotech worth $1,217,000 at the end of the most recent quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.